Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 1601-1626

  Pa, Shu Ting ^a   Qin, Yiru ^b   Zhou, Zhi Wei ^b,c   He, Zhi Xu ^c   Zhang, Xueji ^d   Yang, Tianxin ^e   Yang, Yin Xue ^f   Wang, Dong ^g   Qiu, Jia Xuan ^a   Zhou, Shu Feng ^b  

^a NANCHANG UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c GUIZHOU MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f NINGXIA MEDICAL UNIVERSITY   (China)

^g THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; GSK3 ; p38 MAPK; ROS; TSCC

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; CELL CYCLE PROTEIN; CELL DIVISION CYCLE PROTEIN 2; CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PLUMBAGIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P53; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; WORTMANNIN; NAPHTHOQUINONE; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DRUG STRUCTURE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCC25 CELL LINE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA CELL LINE; TONGUE CARCINOMA; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TONGUE NEOPLASMS; TUMOR CELL CULTURE;

APOPTOSIS; AUTOPHAGY; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MAP KINASE SIGNALING SYSTEM; MOLECULAR STRUCTURE; NAPHTHOQUINONES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; STRUCTURE-ACTIVITY RELATIONSHIP; TONGUE NEOPLASMS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84929208017     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S76057     Document Type: Article

References (70)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
2. Markopoulos AK. Current aspects on oral squamous cell carcinoma. Open Dent J. 2012;6:126-130.
3. Dogan E, Cetinayak HO, Sarioglu S, Erdag TK, Ikiz AO. Patterns of cervical lymph node metastases in oral tongue squamous cell carcinoma: implications for elective and therapeutic neck dissection. J Laryngol Otol. 2014;128(3):268-273.
4. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med. 2013;368(19):1845-1846.
5. Choi KS. Autophagy and cancer. Exp Mol Med. 2012;44(2):109-120.
6. Denton D, Nicolson S, Kumar S. Cell death by autophagy: Facts and apparent artefacts. Cell Death Differ. 2012;19(1):87-95.
7. Fuchs Y, Steller H. Programmed cell death in animal development and disease. Cell. 2011;147(4):742-758.
8. Taylor RC, Cullen SP, Martin SJ. Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9(3):231-241.
9. Green DR. Apoptotic pathways: ten minutes to dead. Cell. 2005;121(5): 671-674.
10. Kurokawa M, Kornbluth S. Caspases and kinases in a death grip. Cell. 2009;138(5):838-854.
11. Padhye S, Dandawate P, Yusufi M, Ahmad A, Sarkar FH. Perspectives on medicinal properties of plumbagin and its analogs. Med Res Rev. 2012;32(6):1131-1158.
12. Sung B, Oyajobi B, Aggarwal BB. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling. Mol Cancer Ther. 2012; 11(2):350-359.
13. Mishra BB, Singh DD, Kishore N, Tiwari VK, Tripathi V. Antifungal constituents isolated from the seeds of Aegle marmelos. Phytochemistry. 2010;71(2-3):230-234.
14. Kuete V, Alibert-Franco S, Eyong KO, et al. Antibacterial activity of some natural products against bacteria expressing a multidrug-resistant phenotype. Int J Antimicrob Agents. 2011;37(2):156-161.
15. Pradeepa V, Sathish-Narayanan S, Kirubakaran SA, Senthil-Nathan S. Antimalarial efficacy of dynamic compound of plumbagin chemical constituent from Plumbago zeylanica Linn (Plumbaginaceae) against the malarial vector Anopheles stephensi Liston (Diptera: Culicidae). Parasitol Res. 2014;113(8):3105-3109.
16. Checker R, Patwardhan RS, Sharma D, et al. Plumbagin, a vitamin K3 analogue, abrogates lipopolysaccharide-induced oxidative stress, inflammation and endotoxic shock via NF-κB suppression. Inflammation. 2014;37(2):542-554.
17. Sharma I, Gusain D, Dixit VP. Hypolipidaemic and antiatherosclerotic effects of plumbagin in rabbits. Indian J Physiol Pharmacol. 1991;35(1): 10-14.
18. Zhang K, Ge Z, Da Y, et al. Plumbagin suppresses dendritic cell functions and alleviates experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014;273(1-2):42-52.
19. Sinha S, Pal K, Elkhanany A. Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer. 2013;132(5): 1201-1212.
20. Qiu JX, He YQ, Wang Y. Plumbagin induces the apoptosis of human tongue carcinoma cells through the mitochondria-mediated pathway. Med Sci Monit Basic Res. 2013;19:228-236.
21. Xu TP, Shen H, Liu LX, Shu YQ. Plumbagin from Plumbago zeylanica L induces apoptosis in human non-small cell lung cancer cell lines through NF-κB inactivation. Asian Pac J Cancer Prev. 2013;14(4): 2325-2331.
22. Hsu YL, Cho CY, Kuo PL, Huang YT, Lin CC. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther. 2006;318(2):484-494.
23. Kuo P, Hsu YL, Cho CY. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther. 2006;5(12):3209-3221.
24. Li YC, He SM, He ZX, et al. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Lett. 2014; 344(2):239-259.
25. Sun J, McKallip RJ. Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression. Leuk Res. 2011;35(10):1402-1408.
26. Kumar S, Gautam S, Sharma A. Antimutagenic and antioxidant properties of plumbagin and other naphthoquinones. Mutat Res. 2013; 755(1):30-41.
27. Ma S, Li Q, Pan F. CXCR4 promotes GSK3β expression in pancreatic cancer cells via the Akt pathway. Int J Clin Oncol. Epub 2014 Aug 23.
28. Kao SH, Wang WL, Chen CY, et al. GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene. 2014;33(24):3172-3182.
29. Zeng J, Liu D, Qiu Z, et al. GSK3β overexpression indicates poor prognosis and its inhibition reduces cell proliferation and survival of non-small cell lung cancer cells. PLoS One. 2014;9(3):e91231.
30. Zhang JS, Herreros-Villanueva M, Koenig A, et al. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells. Cell Death Dis. 2014;5:e1142.
31. Gavilán E, Sánchez-Aguayo I, Daza P, Ruano D. GSK-3β signaling determines autophagy activation in the breast tumor cell line MCF7 and inclusion formation in the non-tumor cell line MCF10A in response to proteasome inhibition. Cell Death Dis. 2013;4:e572.
32. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 1994; 265(5173):808-811.
33. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal. 2000;12(1):1-13.
34. Sui X, Kong N, Ye L, et al. p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett. 2014;344(2):174-179.
35. Zhou CH, Pan J, Huang H, et al. Salusin-β, but not salusin-α, promotes human umbilical vein endothelial cell inflammation via the p38 MAPK/JNK-NF-κB Pathway. PLoS One. 2014;9(9):e107555.
36. Kobayashi M, Takeyoshi I, Yoshinari D, Matsumoto K, Morishita Y. P38 mitogen-activated protein kinase inhibition attenuates ischemia-reperfusion injury of the rat liver. Surgery. 2002;131(3):344-349.
37. Yang DP, Kim J, Syed N, et al. p38 MAPK activation promotes denervated Schwann cell phenotype and functions as a negative regulator of Schwann cell differentiation and myelination. J Neurosci. 2012; 32(21):7158-7168.
38. Leelahavanichkul K, Amornphimoltham P, Molinolo AA, Basile JR, Koontongkaew S, Gutkind JS. A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis. Mol Oncol. 2014;8(1):105-118.
39. Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013;13(9):679-692.
40. Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer. 2013;4(9-10):342-359.
41. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011;1813(11):1978-1986.
42. Rabinowitz JD, White E. Autophagy and metabolism. Science. 2010;330(6009):1344-1348.
43. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011;18(4):571-580.
44. Maiuri MC, Criollo A, Kroemer G. Crosstalk between apoptosis and autophagy within the Beclin 1 interactome. EMBO J. 2010;29(3): 515-516.
45. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19(21):5720-5728.
46. Aziz MH, Dreckschmidt NE, Verma AK. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res. 2008;68(21): 9024-9032.
47. Wang CC, Chiang YM, Sung SC, Hsu YL, Chang JK, Kuo PL. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett. 2008;259(1):82-98.
48. Estaquier J, Vallette F, Vayssiere JL, Mignotte B. The mitochondrial pathways of apoptosis. Adv Exp Med Biol. 2012;942:157-183.
49. Richter-Larrea JA, Robles EF, Fresquet V, et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood. 2010;116(14):2531-2542.
50. Ahmad A, Banerjee S, Wang Z, Kong D, Sarkar FH. Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF-kB and Bcl-2. J Cell Biochem. 2008;105(6):1461-1471.
51. Ding YH, Zhou ZW, Ha CF, et al. The Aurora kinase A inhibitor alisertib induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells. Drug Des Devel Ther. 2015;9:425-464.
52. Pennington K, Pulaski H, Pennington M, Liu JR. Too much of a good thing: suicide prevention promotes chemoresistance in ovarian carcinoma. Curr Cancer Drug Targets. 2010;10(6):575-583.
53. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9-22.
54. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012;18(21): 5856-5864.
55. Wozney JL, Antonarakis ES. Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev. 2014;33(2-3):581-594.
56. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143-153.
57. Zielinski RR, Eigl BJ, Chi KN. Targeting the apoptosis pathway in prostate cancer. Cancer J. 2013;19(1):79-89.
58. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290(5497):1717-1721.
59. Piazza F, Manni S, Semenzato G. Novel players in multiple myeloma pathogenesis: Role of protein kinases CK2 and GSK3. Leuk Res. 2013; 37(2):221-227.
60. Kim TW, Michniewicz M, Bergmann DC, Wang ZY. Brassinosteroid regulates stomatal development by GSK3-mediated inhibition of a MAPK pathway. Nature. 2012;482(7385):419-422.
61. Gao C, Hölscher C, Liu Y, Li L. GSK3: A key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosci. 2012;23(1):1-11.
62. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics. Neurochem Res. 2007; 32(4-5):577-595.
63. Hernandez F, Lucas JJ, Avila J. GSK3 and tau: Two convergence points in Alzheimer’s disease. J Alzheimers Dis. 2013;33 (Suppl 1):S141-S144.
64. Zimmermann C, Santos A, Gable K, et al. TORC1 inhibits GSK3-mediated Elo2 phosphorylation to regulate very long chain fatty acid synthesis and autophagy. Cell Rep. 2013;5(4):1036-1046.
65. Niu S, Yuan D, Jiang X, Che Y. 11′-Deoxyverticillin A (C42) promotes autophagy through K-Ras/GSK3 signaling pathway in HCT116 cells. Protein Cell. 2014;5(12):945-949.
66. Lin SY, Li TY, Liu Q, et al. GSK3-TIP60-ULK1 signaling pathway links growth factor deprivation to autophagy. Science. 2012;336(6080):477-481.
67. Kurosu T, Nagao T, Wu N, Oshikawa G, Miura O. Inhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis. PLoS One. 2013;8(11):e79478.
68. Rahmani M, Aust MM, Attkisson E, Williams DC Jr, Ferreira-Gonzalez A, Grant S. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res. 2013;73(4): 1340-1351.
69. Yang J, He J, Wang J, et al. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia. 2012;26(9):2114-2123.
70. Xu KH, Lu DP. Plumbagin induces ROS-mediated apoptosis in human promyelocytic leukemia cells in vivo. Leuk Res. 2010;34(5):658-665.